 Unity Bio was previously advancing a lead candidate aimed at reducing osteoarthritis pain by selectively clearing senescent cells in the knee. This candidate, UBX0101, was dropped by the company on August 17 due to it failing to meet its primary endpoint in Unitys ongoing Phase 2 for that indication. 